bioRxiv · 10.64898/2025.12.02.691773
Mapping the latent CRBN-molecular glue degrader interactome
Abstract
Molecular glue degraders (MGDs) are a transformative modality in drug discovery. MGDs that work in concert with the E3 ligase CRL4CRBN can degrade a range of substrates through tailored MGDs. To explore CRL4CRBN reprogrammability, we tested whether reported CRBN-MGD substrates are part of a network of latent CRBN interactors, detectable with generic CRBN-MGDs. Leveraging highly parallel interaction measurement (GluePCA) between CRL4CRBN and human zinc-fingers (ZFs), we identified [~]210 ZFs bound to CRBN-pomalidomide, where top binders are already reported as degraded by dedicated MGDs. To map latent CRBN-MGDs interactions proteome-wide, and thus define the immediately accessible CRBN target space, we combined AI-derived protein surface queries (MaSIF-mimicry) with GluePCA. This pipeline identified 6 known and 43 novel CRBN-pomalidomide binders, thereby providing privileged starting points for MGD development. We expect this binding-focused, highly parallel workflow to be readily applicable to other MGD/E3 ligase systems, extending the target landscape of this emerging drug class.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Galli, P., Xiao, S., Meng, Y., Hanzl, A., Bendel, A. M., Aguirre, J. D., Diaz-Rovira, A. M., Stammnitz, M. R., Kempf, G., Kater, L., Shimada, K., Wei, Y., Scheck, A., Klein, D., Cavadini, S., Diss, G., Correia, B. E., Thomae, N. H.. 2025-12-02. Mapping the latent CRBN-molecular glue degrader interactome. https://doi.org/10.64898/2025.12.02.691773
Cite the original work for its findings. Save a collection to share your selection of sources.